Our department has a pivotal role in the development of advanced cell therapy and translational research at Kyoto University Hospital. Not only to pursue the safe and the efficient transfusion practice in the hospital, but we supply well-manufactured human tissues/cells to clinical settings for stem cell transplantations and novel cell therapies or regenerative therapies. Through investigation of the regulation of hematopoiesis and the biology of mesenchymal stem cells, we are aiming at developing innovative and translational cell therapy, regenerative therapy, and molecular target therapy for hematological disorders and other malignancies.
Research and EducationOur primary mission is to provide safe, efficient and high-quality patient care and hospital services by utilizing a computer-assisted intelligent system. Our secondary mission is to develop advanced medical care and therapies based on scientifically robust data. We are developing novel diagnostic methods for transplantation and cell therapy. In addition, we are manipulating hematopoietic stem cells, mesenchymal stem cells, pancreas islet cells and other tissue- or iPS- derived cells for transplantation or cell therapy at our cell processing center, Center for Cell and Molecular Therapy (CCMT). For basic research, we are currently working on the following projects; a) molecular mechanisms involved in the normal, stress and leukemic hematopoiesis, and b) regulation of the normal and abnormal hematopoiesis and the immune system by mesenchymal stem cells (MSCs). All of these projects are aiming at the future development of novel therapeutics for currently incurable diseases. We are providing educational programs and hands-on trainings of transfusion medicine for students of the faculty of medicine and human science and residents
① Elucidation of molecular mechanisms involved in the regulation of normal , stress and abnormal hematopoiesis.
② Mesenchymal stem cell-mediated regulation of hematopoiesis, and immune system.
Recent Publications1. Tamura A, Hirai H, Yokota A, Kamio N, Sato A, Shoji T, Kashiwagi T, Torikoshi Y, Miura Y, Tenen DG and Maekawa T: C/EBPβ is required for survival of Ly6C- monocytes. Blood. 2017 Oct 19;130(16):1809-1818.
2. Yokota A, Hirai H, Shoji T, Maekawa T and Okuda K: Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo. Leukemia. 2017 Dec;31(12):2742-2751.
3. Hayashi Y, Hirai H, Kamio N, Yao H, Yoshioka S, Miura Y, Ashihara E, Fujiyama Y, Tenen DG and Maekawa T: C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. Leukemia. 2013 Mar;27(3):619-28.
4. Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T and Maekawa T: Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations. Stem Cells. 2018 Mar;36(3):434-445.
5. Fujishiro A, Miura Y, Iwasa M, Fujii S, Sugino N, Andoh A, Hirai H, Maekawa T, Ichinohe T. Effects of acute exposure to low-dose radiation on the characteristics of human bone marrow mesenchymal stromal/stem cells. Inflamm Regen. 2017; 37:19.
Transfusion Medicine and Cell TherapySenior Lecturer: Hideyo Hirai